Reversible Effects of Stopping Oral Contraceptives on Brain Serotonin Receptors
Official title: Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission
Run by Copenhagen University Hospital, Rigshospitalet · NCT07511439 · Data updated 2026-11-12
This study tests whether stopping a common birth control pill increases brain serotonin 4 receptor binding in healthy adult women who have been using a second-generation pill.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 39 Years |
| Sex | Women only |
| Enrollment | 60 (estimated) |
| Sponsor | Copenhagen University Hospital, Rigshospitalet Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Copenhagen) |
| Status | Recruiting |
| Started | April 23, 2026 |
| Main results expected | December 31, 2030 |
| Study ends | December 31, 2030 |
| Registry record updated | July 2, 2026 |
| Trial ID | NCT07511439 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy women aged 18-39 who have used a second-generation COC (150 µg levonorgestrel and 30 µg ethinylestradiol) for at least 3 months.
✕Probably not a fit
People with current or past neurological/psychiatric disorders or those unable to comply with study procedures may not experience benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will randomly assign healthy women aged 18-39 who currently use a specific combined oral contraceptive to discontinue or continue use for up to one year. Brain imaging with PET will measure 5-HT4 receptor binding at baseline and after follow-up to see if stopping the pill restores receptor levels toward those seen in non-users. The study also explores how changes relate to mood, memory, and sexual desire, with the goal of understanding whether any COC-related brain changes are reversible. Up to 60 participants will be enrolled at Copenhagen University Hospital, Rigshospitalet, with careful screening for MRI safety and other eligibility factors.
Why it matters
Potential benefit: If successful, the study could clarify whether COC-related brain changes are reversible and inform strategies for managing mood-related side effects.
How similar studies have gone: Previous work suggests COC use reduces 5-HT4 receptor levels, and disrupting use may allow recovery, supporting a plausible effect in this study.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Healthy women (assigned female at birth) at 18-39 years of age 2. Currently using a second-generation combined oral contraceptive containing 150 ug levonorgestrel and 30 ug ethinylestradiol for at least 3 months Exclusion Criteria: 1. Current or previous neurological or psychiatric disease, severe somatic disease, or consumption of medical drugs (including psychoactive medication) likely to influence the test results 2. Non-fluent in Danish or pronounced visual or auditory impairments 3. Current or past learning disability 4. Pregnancy within the last year or previous pregnancy lasting into second or third trimester 5. A wish to become pregnant within the following 12 months 6. Participation in experiments with exposure to radioactivity (\> 10 mSv) within the last year or significant occupational exposure to radioactivity 7. Contraindications for MRI (pacemaker, metal implants, claustrophobia) 8. A history of head injury or concussion resulting in loss of consciousness for more than 2 min 9. Alcohol or drug abuse 10. Drug use other than tobacco and alcohol within the last 30 days 11. Cannabis \> 50 x lifetime 12. Recreational drugs other than cannabis \> 10 x lifetime (for each substance) 13. Nicotine addiction 14. Non-compliance to COC within the last 3 months (i.e., \> 2 missed pills in a cycle) 15. Contraindication for use of combined oral contraception
Where it's running
-
Neurobiology Research Unit (NRU)
Copenhagen, Denmark Recruiting
Study contacts
- Principal investigator: Søren Vinther Larsen, MD, PhD — Neurobiology Research Unit, Rigshospitalet
- Study coordinator: Søren Vinther Larsen, MD, PhD
- Email: soren.vinther@nru.dk
- Phone: +45 35456708
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Biomarker test for brown rice components in healthy adults
This study will test whether specific biomarkers in blood and urine reflect acute brown rice intake in healthy men and women.
-
Dermial skin-brightening supplement study in healthy adult women
A daily 60 mg Dermial® supplement or placebo is being tested for 12 weeks to see if it improves skin brightness and related signs in healthy women aged 35–65 with mild to moderate facial ageing.
-
Pharmacokinetics of Whole-Grain Corn: What Happens After Eating
This study tests how healthy adults absorb and excrete components from whole-grain corn by giving two types of corn on different days and measuring biomarkers in blood, urine, and feces.
-
Inhaling hydrogen before exercise to see how the body uses energy in healthy women
This study tests whether inhaling molecular hydrogen for a week changes metabolic responses during graded exercise in healthy young women.
-
Biphasic IVM for POSEIDON Group 1 in young women with poor response
This trial tests whether a two-step in vitro maturation process can help young women with normal ovarian reserve who retrieve too few eggs after standard stimulation.
-
Olive oil extract for improving knee comfort and function
This will test whether taking an olive oil extract every day for six weeks helps reduce knee pain and improve knee function in adults 40–75 who have ongoing knee discomfort.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.